Close Menu

NEW YORK (360Dx) –Vermillion and Quest Diagnostics have agreed to extend and amend their commercialization and services agreement for Vermillion's OVA1 ovarian cancer test.

In a March 1, 2018 filing with the US Securities and Exchange Commission, Vermillion said it has amended the agreement to extend the term from March 11, 2018 to March 11, 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.